All In Biotech

Free tool

FAERS Monitor: Mavenclad

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022561 or its brand name (Mavenclad, Cladribine). Reports on generic versions are filed under their own applications.

Reports

9,967

Serious

7,443

75% of reports

Hospitalization

2,318

Death reported

717

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue848
  • headache713
  • lymphocyte count decreased507
  • multiple sclerosis relapse494
  • nausea437
  • pneumonia418
  • white blood cell count decreased376
  • off label use339
  • drug ineffective309
  • pyrexia294
  • urinary tract infection288
  • multiple sclerosis270
  • asthenia252
  • lymphopenia238
  • febrile neutropenia218

Reports by year received

View as table
YearReports
200424
200526
200618
200717
200819
200929
201053
2011120
2012125
201390
201456
201573
201671
2017117
2018109
2019705
2020954
20211,056
20221,134
20231,333
20241,333
20251,427
20261,078

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,192 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lymphocyte count decreasedSignal50762.357.229,665
lymphopeniaSignal23836.131.87,957
multiple sclerosis relapseSignal49415.314.06,569
multiple sclerosisSignal27012.010.62,696
white blood cell count decreasedSignal3767.36.62,057
febrile neutropeniaSignal2187.06.11,105
urinary tract infectionSignal2883.63.2533
pneumoniaSignal4182.72.5462
headacheSignal7132.42.2599
fatigueSignal8482.32.2645
pyrexia2941.81.6104
asthenia2521.41.331
nausea4371.21.110
off label use3390.80.714
drug ineffective3090.50.4170

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.